by John Conrad | Jul 8, 2024 | NewsBrief
SGS North America has announced a significant expansion of its biologics testing capabilities at its Lincolnshire Center of Excellence in Illinois. This move strengthens the company’s presence in the state and positions it to better serve the growing...
by John Conrad | Jun 28, 2024 | iBIO News
NewsBrief Weekly News Quiz: June 28 Friday Biotech Brainteaser: iBIO’s Weekly Quiz Challenge! 🧪🔬 Calling all life science aficionados! It’s time to flex those mental muscles and dive into our latest biotech knowledge test. How well have you kept up with...
by John Conrad | Jun 28, 2024 | NewsBrief
AbbVie continues to bolster its immunology portfolio beyond Humira, announcing on Thursday its acquisition of early-stage biotech Celsius Therapeutics for $250 million in cash. This move aims to strengthen AbbVie’s longer-term prospects in inflammatory bowel...
by John Conrad | Jun 28, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based biopharmaceutical company, has made a significant move in the biosimilars market by acquiring exclusive U.S. commercial rights to YUSIMRY® (adalimumab-aqvh), a biosimilar of the widely-used drug Humira®. This strategic...
by John Conrad | Jun 27, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM) has achieved a significant milestone in the field of artificial intelligence and precision medicine. The company recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative...
